ArticleNanomaterials (Basel, Switzerland)2020
Mechanistic Insights into the Release of Doxorubicin from Graphene Oxide in Cancer Cells.
Article in Nanomaterials (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Interplay between material properties and cellular effects drives distinct pattern of interaction of graphene oxide with cancer and non-cancer cells.Journal of nanobiotechnology · 2025Article
- Preparation and Evaluation of pH-Sensitive Chitosan/Alginate Nanohybrid Mucoadhesive Hydrogel Beads: An Effective Approach to a Gastro-Retentive Drug Delivery System.Pharmaceutics · 2024Article
- The influence of protein corona on Graphene Oxide: implications for biomedical theranostics.Journal of nanobiotechnology · 2023Review
- Hydrogel-Inducing Graphene-Oxide-Derived Core-Shell Fiber Composite for Antibacterial Wound Dressing.International journal of molecular sciences · 2023Article
- Recent Advances in Nanomaterials of Group XIV Elements of Periodic Table in Breast Cancer Treatment.Pharmaceutics · 2022Review
- The protein corona reduces the anticancer effect of graphene oxide in HER-2-positive cancer cells.Nanoscale advances · 2022Article
- Green decoration of graphene oxide Nano sheets with gelatin and gum Arabic for targeted delivery of doxorubicin.Biotechnology reports (Amsterdam, Netherlands) · 2022Article
- Nanomaterial-Based Drug Delivery Systems: A New Weapon for Cancer Immunotherapy.International journal of nanomedicine · 2022Review
- FLIM as a Promising Tool for Cancer Diagnosis and Treatment Monitoring.Nano-micro letters · 2021Review
- Nanomaterials for cancer therapy: current progress and perspectives.Journal of hematology & oncology · 2021Review
- Advances in Drug Delivery Nanosystems Using Graphene-Based Materials and Carbon Nanotubes.Materials (Basel, Switzerland) · 2021Review
- Synergistic Analysis of Protein Corona and Haemoglobin Levels Detects Pancreatic Cancer.Cancers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liposomal doxorubicin (L-DOX) is a popular drug formulation for the treatment of several cancer types (e.g., recurrent ovarian cancer, metastatic breast cancer, multiple myeloma, etc.), but poor nuclear internalization has hampered its clinical applicability so far. Therefore, novel drug-delivery nanosystems are actively researched in cancer chemotherapy. Here we demonstrate that DOX-loaded graphene oxide (GO), GO-DOX, exhibits much higher anticancer efficacy as compared to its L-DOX counterpart if administered to cellular models of breast cancer. Then, by a combination of live-cell confocal imaging and fluorescence lifetime imaging microscopy (FLIM), we suggest that GO-DOX may realize its superior performances by inducing massive intracellular DOX release (and its subsequent nuclear accumulation) upon binding to the cell plasma membrane. Reported results lay the foundation for future exploitation of these new adducts as high-performance nanochemotherapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.